Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01158170

Enrollment

200

Registered

2010-07-08

Start date

2010-06-30

Completion date

2013-12-31

Last updated

2010-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

nonsmall cell lung cancer, brain metastasis, prophylactic cranial irradiation

Brief summary

RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in patients with advanced non-small cell lung cancer. It is not yet known whether radiation therapy is more effective than observation in patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to the brain to see how well it works compared with observation in preventing brain metastases in patients with advanced non-small cell lung cancer

Detailed description

OBJECTIVES: Primary Determine the effectiveness of prophylactic cranial radiotherapy in patients with advanced non-small cell lung cancer that is responsive to gefitinib or erlotinib hydrochloride. Secondary Determine the progression-free survival in patients treated with this regimen. Determine the overall survival in patients treated with this regimen. Determine the safety and tolerability of this regimen in these patients. Determine the psycho-neurological effects of this regimen in these patients. Determine the quality of life of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients with good response( CR/PR) to EGFR-TKI(Erlotinib or Gefitinib) are randomized to receive EGFR-TKI plus PCI or EGFR-TKI alone,stratified according to prior chemotherapy regimens (first line vs second line), and disease response status. Group 1: Patients undergo prophylactic brain radiotherapy. Group 2: Patients undergo observation. Patients complete quality of life questionnaires periodically. After completion of study therapy, patients are followed up periodically.

Interventions

RADIATIONProphylactic cranial irradiation

25GY/10fraction

DRUGErlotinib /Gefitinib

Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Patients were required to have histologically or cytologically documented 2. NSCLC and no brain metastasis documented by magnetic resonance imaging (MRI)within 21 days after confirmed response (RR+SD) to chemotherapy 3. No previous history of radiotherapy and surgery of brain 4. good response( CR/PR) to Erlotinib or Gefitinib. 5. Agree to radiotherapy 6. age \> 18 and \<75 years,ECOG performance status 1 or less 7. Good renal and hepatic and haematological (absolute neutrophils count 15 x1O9/L and platelet count 90 x 109/L,HB\>=80g /DL) functions 8. Have provided informed consent

Exclusion criteria

1. Seizure cannot be controled by the drugs 2. Combined with other disease of the brain such as tumour or infarction 3. Hypersensitivity to MR enhancer -

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the cumulative incidence of symptomatic brain metastases (BM)	2.5years

Secondary

Measure	Time frame
overall survival	baseline to date of death from any cause

Countries

China

Contacts

Primary ContactShenglin Ma, MD

mashenglin@medmail.com.cn+8657188122568

Backup ContactYaping Xu, MD

xuyaping1207@gmail.com+8657188122082

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026